Ecopipam

http://dbpedia.org/resource/Ecopipam an entity of type: Thing

Ecopipam (development codes SCH-39166, EBS-101, and PSYRX-101) is a dopamine antagonist which is under development for the treatment of Lesch-Nyhan syndrome, Tourette's syndrome, speech disorders, and restless legs syndrome. It is taken by mouth. rdf:langString
rdf:langString Ecopipam
xsd:integer 23683974
xsd:integer 1121386226
rdf:langString none
xsd:integer 19
xsd:integer 112108
xsd:integer 97053
xsd:integer 1
xsd:integer 20
rdf:langString Ecopipam-3D-balls.png
rdf:langString -trans-6,7,7a,8,9,13b-Hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naptho-azepine
rdf:langString Investigational
xsd:integer 1
xsd:integer 1
xsd:integer 107930
rdf:langString CN1CCc2ccCl
xsd:integer 1
rdf:langString DMJWENQHWZZWDF-PKOBYXMFSA-N
rdf:langString EBS-101; PSYRX-101; SCH-39166
xsd:integer 0
xsd:integer 444234555
rdf:langString changed
rdf:langString Ecopipam (development codes SCH-39166, EBS-101, and PSYRX-101) is a dopamine antagonist which is under development for the treatment of Lesch-Nyhan syndrome, Tourette's syndrome, speech disorders, and restless legs syndrome. It is taken by mouth. Ecopipam acts as a selective dopamine D1 and D5 receptor antagonist. It is orally active, has an elimination half-life of 10 hours, crosses the blood–brain barrier, and substantially occupies brain dopamine receptors. Side effects of ecopipam may include depression, anxiety, fatigue, sedation, somnolence, insomnia, headaches, muscle twitching, and suicidal ideation, among others. It appears to lack the typical extrapyramidal effects like tardive dyskinesia that occur with D2 receptor antagonists. Ecopipam is an experimental drug and has not been approved for medical use. As of April 2022, it is in phase 3 trials for Lesch-Nyhan syndrome, phase 2 trials for Tourette's syndrome and speech disorders, and phase 2/phase 1 trials for restless legs syndrome. The drug was also under development for the treatment of cocaine-related disorders, obesity, and schizophrenia, but development for these indications was discontinued.
xsd:integer 3304
xsd:nonNegativeInteger 14751
xsd:string 112108-01-7
xsd:string 0X748O646K
xsd:string 107930

data from the linked data cloud